Home infusions of ocrelizumab for some people with MS
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at giving ocrelizumab treatments at home instead of in a clinic for people with MS. It’s meant to see if this approach is practical and acceptable while you keep receiving a medicine your MS doctor thinks you should continue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently being followed at the Rocky Mountain MS Center in Colorado
- You are between 18 and 55 years old when you sign up
- You have primary progressive MS or relapsing MS (a specific MS diagnosis standard)
- You live in the Denver metro, Fort Collins, or Colorado Springs area
- You have already completed your first 600 mg dose of ocrelizumab
- Your MS disability score (PDDS) is between 0 and 6.5
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
This extension study continues treatment with ocrelizumab for people with multiple sclerosis who are already taking it as part of a parent trial, to see how MS affects physical function over a longer time. It helps ensure you can keep receiving ocrelizumab even if it's not available where you live.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This study looks at how ocrelizumab treatment affects a nerve health marker called neurofilament light chain (NfL) and how satisfied you are with the treatment. It may help doctors understand if this medicine works well for people with multiple sclerosis.
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.